I wholeheartedly concur! The current trajectory appears exceedingly promising over the three-month period you referenced. I eagerly anticipate the outcomes of the Phase 2 trials in Pitt Hopkins syndrome and Angelman syndrome, given the significant potential attributed to NNZ-2591, which surpasses that of Rett Syndrome by more than fivefold. I perceive a confluence of favorable factors. Furthermore, the noteworthy achievement of a $157 million profit after tax for 2023 adds to the company's compelling narrative.
- Forums
- ASX - By Stock
- Medium term milestones
I wholeheartedly concur! The current trajectory appears...
Featured News
Add NEU (ASX) to my watchlist
(20min delay)
|
|||||
Last
$19.97 |
Change
0.000(0.00%) |
Mkt cap ! $2.552B |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 500 | $20.00 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$18.98 | 302 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 500 | 20.000 |
2 | 39 | 19.970 |
1 | 30 | 19.950 |
1 | 50 | 19.850 |
1 | 26 | 19.810 |
Price($) | Vol. | No. |
---|---|---|
18.980 | 302 | 3 |
19.380 | 9 | 1 |
19.770 | 39 | 2 |
19.960 | 18 | 1 |
19.970 | 1142 | 2 |
Last trade - 09.31am 05/07/2024 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |
Day chart unavailable